KANGHONG
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

KANGHONG Trademark

Serial Number: 79245594 • Registration: 5876519

KANGHONG is a trademark filed by Chengdu Kanghong Pharmaceuticals Group Co., Ltd. on May 22, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Chengdu Kanghong Pharmaceuticals Group Co., Ltd. (7 trademarks)

No.36, Shuxi Rd.,
Sichuan , CN

Entity Type: 99

Trademark Details

Filing Date

May 22, 2018

Registration Date

October 8, 2019

Published for Opposition

July 23, 2019

Cancellation Date

April 24, 2026

Goods & Services

Mothproofing preparations; Radioactive substances in the nature of drugs for medical purposes; Chemico-pharmaceutical preparations for reducing blood fat; Chemico-pharmaceutical preparations for promoting sleep; Chemico-pharmaceutical preparations for sedation, anti-depression, tumor suppression; Chemico-pharmaceutical preparations for the treatment of diabetes, diseases of the central nervous system, diseases of the respiratory system, cardiovascular diseases and cancer; Chemico-pharmaceutical preparations used in eye surgery and intraocular surgery; Pharmaceutical preparations in the nature of tissues impregnated with pharmaceutical skin lotions; Depuratives for the body; Media for bacteriological cultures; Medicinal preparations for the mouth to be applied in the form of tablets; Semen for artificial insemination; Medicines for human purposes, namely, medicines for humans for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; Medicines for humans to treat or prevent diabetes, coughs, colds, influenza, headaches and allergic reactions; Vermin destroying preparations; Biochemical drug for medical purposes for the treatment of cancer and ophthalmic diseases; Suppositories; Pharmaceutical preparations in the form of liquids for the treatment of central nervous system diseases, tumors, diabetes, ophthalmic diseases; Pharmaceutical preparations in the form of liquids for the treatment of cancer; Disinfectants for hygiene purposes; Mosquito-repellent incense; Sanitary sterilizing preparations in the nature of tissues impregnated with sterilization preparations; Chemical conductors for electrocardiograph electrodes; Dental lacquer; Medicinal drinks in the nature of herb liqueurs; Pharmaceutical preparations used for the relief of pain and to reduce fever; Pharmaceutical preparations for the prevention and/or treatment of cardiovascular diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; Pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors; anti-infective pharmaceutical preparations; Pharmaceutical preparations, namely, ophthalmics; Pharmaceutical preparations for the treatment of ophthalmic diseases and conditions; Infusions for medical purposes for treating dermatological diseases; Gases for medical purposes; Wadding for medical purposes; Drugs for medical purposes, namely, pharmaceutical preparations for anti-depression, tumor suppression, relieving cough, reducing blood pressure; Drugs for medical purposes, namely, pharmaceutical preparations for the treatment central nervous system diseases, asthma, diabetes, respiratory system diseases, cancer, cardiovascular diseases, gastrointestinal diseases, hyperlipidaemia and hypercholesteremia; Drugs for medical purposes, namely, pharmaceutical preparations used in eye surgery and intraocular surgery; Bath preparations for medical purposes; Diagnostic agents for medical purposes; Solutions for contact lenses; Crude drugs, namely pharmaceutical preparations for the treatment of central nervous system diseases, namely hypertension, hyperlipidemia, schizophrenia and melancholia, digestive system diseases, namely dyspepsia, chronic gastritis, chronic lithogenous cholecystitis, chronic cholecystitis and gall-stone, ophthalmology system diseases, namely wet Age-related Macular Degeneration (AMD), and other diseases, namely fever, irritability, red eyes, mouth sores, sore throat, swollen gums, constipation, pharyngitis, tonsillitis, gingivitis, upper respiratory infection (URI), acute bronchitis, diabetes and nephropathy; Pharmaceutical preparations in the form of injections for the treatment of central nervous system diseases, diabetes, fundus oculi disease and cancer; Pharmaceutical preparations in the form of injections for tumor suppression; Pharmaceutical preparations in the form of injections used in eye surgery and intraocular surgery; Traditional Chinese medicines for Chinese medicinal use, namely, dried Chinese boxthorn fruits, Chinese-date, pseudo-ginseng, Chinese angelica and ginseng; Traditional Chinese medicines for Chinese medicinal use, namely, dried Chinese boxthorn fruits, Chinese-date, pseudo-ginseng, Chinese angelica and ginseng sold as a kit in a Chinese medicine bag

Filing History

CANCELLED SECTION 71
Apr 24, 2026 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 8, 2024 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jun 9, 2024 NREP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 10, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 10, 2022 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 10, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 10, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 10, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 10, 2022 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 13, 2020 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Feb 3, 2020 XXSS
GENERIC MADRID TRANSACTION CREATED
Feb 3, 2020 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 8, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 8, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 23, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jul 23, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 3, 2019 NONP
ASSIGNED TO LIE
Jun 14, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 31, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 10, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 9, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 9, 2019 TROA
REFUSAL PROCESSED BY IB
Dec 28, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 13, 2018 RFCS
REFUSAL PROCESSED BY MPU
Dec 13, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 30, 2018 RFCR
NON-FINAL ACTION WRITTEN
Nov 29, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Nov 27, 2018 MAFR
ASSIGNED TO EXAMINER
Nov 23, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 23, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 22, 2018 REPR